In a 14-year-old female with depression and suicidal ideation who is taking sertraline 75 mg daily and tapering off aripiprazole (Abilify) 2 mg, and now reports marked increase in energy, restlessness, and urge to move, what is the appropriate management?

Immediate Management: Discontinue Aripiprazole and Assess for Behavioral Activation/Akathisia

This patient is exhibiting classic signs of behavioral activation and/or akathisia—potentially dangerous adverse effects that can emerge during SSRI treatment or when tapering antipsychotics, and you must immediately stop the Abilify taper and evaluate whether the sertraline dose needs adjustment or discontinuation.

Clinical Assessment Priority

The marked increase in energy, inability to sit still, and compulsive urge to move are red flags for two critical conditions:

1. Behavioral Activation/Switch to Mania

The FDA sertraline label explicitly warns that antidepressants can precipitate manic/mixed episodes in patients at risk for bipolar disorder 1. Her symptoms—"really up on energy levels," inability to sit still, excessive movement without purpose—suggest possible activation syndrome or an emerging hypomanic/manic episode.

2. Akathisia

The restlessness and urge to move are textbook akathisia symptoms. This is particularly concerning because:

• Akathisia has been directly linked to suicidal ideation in patients on aripiprazole 2, 3
• The combination of aripiprazole with SSRIs increases akathisia risk 3
• Even low-dose aripiprazole (2mg) can cause akathisia with suicidal thoughts 2
• Guidelines specifically warn about the relationship between SSRI-induced akathisia and suicidality 4

Immediate Action Steps

Stop the Abilify taper immediately. Do not continue tapering—discontinue it now. The research shows akathisia and suicidal ideation can occur even at low doses of aripiprazole, particularly when combined with antidepressants 2, 3.

Assess for bipolar disorder risk factors:

• Detailed psychiatric history including family history of bipolar disorder, suicide, and depression 1
• Prior hypomanic/manic episodes
• Response pattern to antidepressants (has she had activation before?)

Evaluate akathisia severity:

• Ask specifically: Does she feel internally restless or driven to move?
• Is this distressing to her?
• Any worsening of suicidal thoughts coinciding with these symptoms?

Treatment Decision Algorithm

If Akathisia is Present:

• Discontinue aripiprazole completely (already at 2mg, so minimal taper needed)
• Consider propranolol 10-20mg TID or benzodiazepine short-term for akathisia relief
• Monitor closely for resolution of restlessness (should improve within days)

If Behavioral Activation/Possible Mania:

• Hold or reduce sertraline immediately 5, 1
• The GLAD-PC guidelines emphasize monitoring for "switch to mania or development of behavioral activation" as critical adverse events 5
• Urgent psychiatric consultation to rule out bipolar disorder
• If bipolar disorder is confirmed, she needs mood stabilizer before any antidepressant 4

If Symptoms Persist After Stopping Aripiprazole:

• Reduce sertraline dose from 75mg to 50mg or 25mg
• The activation may be from the SSRI itself, not just the aripiprazole interaction
• Guidelines note that starting SSRIs at higher doses increases risk of behavioral activation 5

Monitoring Requirements

Contact within 24-48 hours (phone acceptable per guidelines 5) to assess:

1. Suicidal ideation status—any increase is an emergency
2. Restlessness/akathisia symptoms
3. Sleep pattern (decreased need for sleep suggests mania)
4. Mood elevation vs. just physical restlessness

Weekly contact for 4 weeks to monitor for:

• Resolution of activation symptoms
• Emergence of depressive symptoms after medication changes
• Any new suicidal thoughts 5

Critical Pitfalls to Avoid

Do not continue tapering Abilify slowly. The combination of aripiprazole with sertraline increases akathisia risk, and case reports show suicidal ideation can emerge acutely with this combination 2, 3. Stop it now.

Do not dismiss this as "just anxiety." The temporal relationship between medication changes and new-onset restlessness, combined with her baseline suicidal ideation, makes this a high-risk situation requiring immediate intervention.

Do not add benzodiazepines long-term. While they may help acute akathisia, guidelines warn they can cause disinhibition and increase suicide risk in some patients 4.

Do not assume this will resolve on its own. Behavioral activation and akathisia require active management—they are not transient side effects to "wait out" in a suicidal adolescent 5, 6.

Documentation

Document explicitly:

• Current symptoms consistent with akathisia/behavioral activation
• Immediate discontinuation of aripiprazole
• Assessment of bipolar risk factors
• Suicidal ideation status at this contact
• Plan for close follow-up within 24-48 hours

This patient's presentation demands urgent action given her baseline suicidal ideation and the known association between akathisia and acute suicidal thoughts in patients on aripiprazole-SSRI combinations 2, 3.